CTRI/2022/03/041114尚未招募2 期
A Randomised Controlled Trial Of Triphaladi Gandush With Triphala Churna Internally In Pittaj Mukhapaka With Special Reference To Aphthous Ulcer.
Megha Kamble1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2022年3月20日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- To study combine effect of Triphaladi Gandush with Triphala Churna internally on parameters of Pittaj Mukhapaka.
研究概览
简要总结
The study is Randomised Controlled Trial of Triphaladi Gandush with Triphala Churna internally for 28 days in Pittaj Mukhapaka with special reference to Aphthous Ulcer.This is considered as a compulsory part of PG course at single centre. The primary outcome is to study the combine effect of Triphaladi Gandush with Triphala Churna internally in Pittaj Mukhapaka. The secondary outcome is to study disease Pittaj Mukhapaka according to Ayurveda in detail. To study Aphthous Ulcer with modern point of view in detail. To study Gandush Kalpana in detail. To observe the adverse effect if any.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 16.00 Year(s) 至 50.00 Year(s)（—）
- 性别
- All
入选标准
- •Patients having signs and symptoms of Pittaj Mukhapaka Patients in between age group 16 to 50 years patients will be selected irrespective of cast sex religion and socioeconomical status patients having Pittaj Mukhapaka limited to buccal, labial mucosa and tongue.
排除标准
- •Patient having local lesions of deformity like gingivitis, pyorrhea, candidial ulcer, oral thrush, herpetic ulcer, traumatic etc Previously diagnosed tubercular, syphilitic, diabetic ulcers Immunosuppressive disorders Known oral, throat, tongue malignancy Moderate to severe anaemia OSMF.
结局指标
主要结局
To study combine effect of Triphaladi Gandush with Triphala Churna internally on parameters of Pittaj Mukhapaka.
时间窗: 18 months
次要结局
- To study the disease Pittaj Mukhapaka according to Ayurveda in detail.(To study Aphthous Ulcer in detail with nodern point of veiw.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)TNBC - Triple-Negative Breast CancerBreast CancerNCT04799249G1 Therapeutics, Inc.194
撤回
3 期
Trial on Metoclopramide and Ketoprofen in Acute Migraine of ChildhoodMigraineNCT00557544IRCCS Burlo Garofolo
已完成
3 期
Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)Hepatitis CNCT02252016Merck Sharp & Dohme LLC159
已完成
3 期
Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation (BMT CTN 0403)Idiopathic Pneumonia SyndromePneumoniaNCT00421174National Heart, Lung, and Blood Institute (NHLBI)37
已完成
3 期
AZD0585 Phase III Long-term Study in JapanHypertriglyceridemiaNCT02463071AstraZeneca383